The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In this study, researchers evaluated the safety, immunogenicity, and preliminary clinical activity of GNOS-PV01 monotherapy in MGMT-unmethylated glioblastoma.
Tagrisso plus chemotherapy improved progression-free survival in EGFR-positive NSCLC patients compared to placebo plus chemotherapy, with median survival of 8.4 vs. 4.4 months. Central nervous system ...
Bireociclib plus fulvestrant nearly doubled progression-free survival compared with fulvestrant alone in HR-positive, HER2-negative advanced breast cancer. Benefits were consistent across high-risk ...
The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no significant overall survival benefit. The study was a double-blind, multicenter ...
An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results